• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Pluristem Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    12/28/22 4:01:52 PM ET
    $PSTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PSTI alert in real time by email
    0001158780 false 0001158780 2022-12-22 2022-12-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT PURSUANT

    TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of report (Date of earliest event reported): December 28, 2022 (December 22, 2022)

     

    PLURI INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Nevada   001-31392   98-0351734
    (State or Other Jurisdiction
    of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    MATAM Advanced Technology Park     
    Building No. 5    
    Haifa, Israel   3508409
    (Address of Principal Executive Offices)   (Zip Code)

     

    011 972 74 710 7171

    (Registrant’s telephone number, including area code)

     

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.00001 per share   PLUR   The Nasdaq Global Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 8.01. Other Events.

     

    On December 22, 2022, Pluri Inc. issued a press release which includes a letter from its Chief Executive Officer and President, Mr. Yaky Yanay. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    99.1   Press release dated December 22, 2022  
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document) 

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      PLURI INC.
       
    Date: December 28, 2022 By: /s/ Chen Franco-Yehuda
      Name:  Chen Franco-Yehuda
      Title: Chief Financial Officer

     

     

    2

     

    Get the next $PSTI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PSTI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PSTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Yanay Yaky was granted 334,821 shares, increasing direct ownership by 23% to 1,760,125 units

      4 - Pluri Inc. (0001158780) (Issuer)

      12/22/22 8:56:45 AM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Aberman Zami sold $1,940 worth of shares (2,000 units at $0.97), decreasing direct ownership by 0.13% to 1,491,973 units

      4 - Pluri Inc. (0001158780) (Issuer)

      12/22/22 8:52:59 AM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Aberman Zami bought $145,109 worth of shares (80,616 units at $1.80)

      4 - PLURISTEM THERAPEUTICS INC (0001158780) (Issuer)

      2/14/22 4:00:49 PM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care